Overview of Флукорал

What is Флукорал? (Fluconazole)

Флукорал is a synthetic, systemic antifungal agent containing the active ingredient Fluconazole, designed to control and suppress the growth of various pathogenic fungi and yeasts throughout the body.

Property	Description
Active ingredient	Fluconazole (INN)
Pharmacological class	Azole Antifungal (Triazole subclass)
Forms	Oral capsules, tablets, suspension, and sterile solution for intravenous infusion
Route of Administration	Oral (per os) and Intravenous (parenteral)
Origin	Synthetic (chemically derived)
General Purpose	To suppress the growth of systemic and superficial fungal infections

What Type of Medicine is Флукорал? (Identity and Class)

Флукорал is a medication classified as a systemic antifungal agent, defined by its sole active ingredient, Fluconazole. This compound belongs to the azole antifungal family, specifically the triazole subclass, a grouping that is clinically recognized for its effectiveness against a broad spectrum of fungal organisms. This classification signifies that the medication is readily absorbed into the body’s circulation, allowing it to act on infections deep within tissues and organs, establishing its profile for systemic therapeutic use rather than localized, surface application.

Composition, Forms, and Origin (The Substance Itself)

The drug is a synthetic compound, chemically manufactured as a single-active ingredient product (monotherapy). Флукорал is provided in multiple formats to accommodate different administration needs, including oral dosage options—capsules, tablets, and a liquid oral suspension—as well as a sterile solution for intravenous infusion. This ensures reliable patient care because the bioavailability of orally administered Fluconazole is measured to be high, often exceeding 90% compared with the intravenous route.

General Purpose and Action (High-Level Benefit)

The core function of Флукорал is to inhibit the growth and proliferation of fungi. It works by interfering with the fungus's ability to create ergosterol, an essential component of the fungal cell membrane, resulting in fungistatic activity. This mechanism ensures the medication halts the infectious spread. For instance, in a typical clinical scenario, Флукорал is employed when fungal organisms have been confirmed as the cause of an infection. By blocking this vital process, the medication provides a therapeutic benefit that allows the patient's immune system to contain and ultimately resolve the infection.

Regulatory References

Fluconazole - StatPearls

What side effects are possible with Флукорал?

Possible side effects and safety information

The safety profile of Fluconazole is formally classified in regulatory documents according to both the frequency of occurrence and the System Organ Class (SOC) affected. The information below describes the officially documented adverse effects and safety characteristics.

Frequency-Classified Adverse Reactions

Adverse reactions are grouped into categories based on reporting rates from clinical data:

Common (occurring in ge 1 in 100 patients): These typically involve the nervous system (e.g., headache) and gastrointestinal tract (e.g., nausea, abdominal pain, diarrhoea, vomiting). Increases in liver enzymes are also commonly documented.
Uncommon and Rare reactions include anaemia, seizures, dizziness, taste perversion, and skin effects like urticaria and pruritus. Alopecia, though rare, is also noted.

Serious Adverse Reactions and Systemic Concerns

The regulatory safety profile highlights the potential for rare, serious events across several body systems:

Hepatobiliary Disorders: Serious hepatic toxicity, including rare cases of hepatic failure, hepatocellular necrosis, and hepatitis, has been reported. This effect is usually reversible upon discontinuation, though it has occurred in patients with serious underlying conditions.
Cardiac Disorders: Rare, but serious, effects on heart rhythm, such as QT prolongation and Torsade de pointes, are documented. This necessitates caution, particularly when co-administered with other specific medications.
Skin Disorders: Severe cutaneous reactions, including Stevens-Johnson syndrome and Toxic Epidermal Necrolysis, are classified as rare, potentially serious adverse reactions.

Safety Considerations for Specific Populations

Official labeling includes constraints for certain patient groups:

Renal and Hepatic Impairment: Caution is required in patients with pre-existing kidney or liver dysfunction, as the medication's disposition is affected by reduced renal function.
Pregnancy: The use of high doses (400 to 800 mg/day) during the first trimester has been associated in case reports with distinct congenital anomalies, as noted in regulatory documents.

Regulatory Safety Summary: The official safety documentation defines the full risk profile by classifying effects from common, usually transient reactions to rare, life-threatening systemic outcomes. These constraints define the authoritative safety boundaries for the medicine's use.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Fluconazole (Флукорал) overdose focuses on specific clinical manifestations and immediate required actions. Overexposure may lead to disturbances in the central nervous system, which are formally documented to include hallucinations, fearfulness, and paranoia.

Overdose carries the risk of life-threatening outcomes, primarily involving the cardiac and dermatological systems. These include the potential for QT interval prolongation, the severe arrhythmia Torsade de pointes, and serious reactions such as Stevens-Johnson Syndrome.

Overdose Action	Regulator-Mandated Action
Immediate Help	Seek immediate medical attention for suspected overdose or symptoms of severe cardiac or CNS effects.
Antidote Status	No specific pharmacological antidote is known. Management is symptomatic and supportive.
Drug Removal	Hemodialysis is documented as a procedural measure that significantly reduces plasma concentrations.

Urgent medical help is required for any onset of these severe symptoms. Treatment is based on supportive measures and clinical monitoring. Due to the drug's primary reliance on renal excretion for clearance, patients with impaired kidney function or the elderly are a specific consideration in managing potential overdose toxicity.

Therapeutic Uses of Флукорал

The therapeutic utility of Флукорал is considered relevant across therapeutic domains involving systemic treatment against a wide spectrum of pathogenic fungi and yeasts, including Candida and Cryptococcus organisms. The medication is commonly used to help with infections caused by these organisms and is relevant across acute therapeutic contexts.

Флукорал is applied across domains where additional symptomatic support is needed, including the management of severe systemic fungal diseases (like Candidemia and Cryptococcal Meningitis), symptomatic relief for mucosal and genital candidiasis, and prophylaxis (prevention) of infection in high-risk patient groups. It is relevant in conditions characterized by periods of heightened symptoms, being used when manifestations such as intense itching, burning, soreness, painful swallowing, or persistent systemic fever create noticeable physiological strain.

“The systemic reach of the medicine may assist with managing infectious spread across the body and helps address symptom clusters that may become intense or disruptive.”

This support contributes to improved day-to-day comfort during symptomatic periods by easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Relief for Intense Irritation Флукорал is commonly used to help with fungal infections when symptoms like pruritus (itching) and soreness interfere with daily comfort.

Regulatory References

NIH DailyMed official drug label

Eligibility and Restrictions for Use

Who can and cannot use Флукорал?

The eligibility for Флукорал (Fluconazole) is defined by specific regulatory criteria concerning patient characteristics and pre-existing health status, as stated in official government documents.

Absolute Contraindications

Use is absolutely prohibited (contraindicated) for individuals with documented hypersensitivity or allergy to fluconazole, related azole antifungals, or any non-active ingredients (excipients) in the specific formulation. This includes patients with certain hereditary sugar intolerances (e.g., galactose or fructose intolerance), which prohibit the use of corresponding dosage forms.

Conditional Use and Restrictions

The medicine requires conditional use in several populations. Dosage must be reduced for patients with renal impairment (kidney dysfunction) due to its primary clearance pathway. Caution is also mandatory for patients with liver dysfunction or those with proarrhythmic cardiac conditions (e.g., risk of QT-interval prolongation).

Age and Pregnancy Status

Флукорал is established for use across a wide age range, from term newborn infants through older adults. However, its safety and efficacy for the specific indication of genital candidiasis have not been established in the pediatric population. For pregnant individuals, chronic, high-dose use in the first trimester is contraindicated, while a single, low dose is associated with a distinct, lower regulatory risk. Use during lactation is generally acceptable, though caution is advised.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Co-administration of Флукорал (Fluconazole) with certain other medicinal products can alter the exposure of either or both drugs, primarily due to its documented effect on the Cytochrome P450 ( CYP) enzyme system.

Contraindicated and High-Risk Combinations

Co-administration is contraindicated with medicinal products that are both known to prolong the QT interval and are metabolized via the CYP3A4 enzyme. Specific medicines explicitly restricted in regulatory documents include pimozide, quinidine, and erythromycin.

Clinically Significant Pharmacokinetic Interactions

Флукорал is a documented inhibitor of CYP2C9 and CYP2C19, and a moderate inhibitor of CYP3A4. This mechanism can significantly increase the systemic exposure of co-administered medicines, including warfarin, certain sulfonylureas, and some statins ( HMG-CoA reductase inhibitors). For example, co-administration with warfarin has been shown to increase the AUC of the potent S-warfarin by over 180% in studies cited in regulatory labeling. The exposure of oral contraceptive components is also documented to be increased. Other interacting classes include anticoagulants, immunosuppressants (e.g., cyclosporine, tacrolimus), and certain anticonvulsants (e.g., phenytoin, carbamazepine).

Other Exposure Modifying Substances

Co-administration with hydrochlorothiazide is documented to increase the exposure ( AUC) of fluconazole itself, while administration of cimetidine two hours prior to fluconazole is documented to significantly decrease fluconazole exposure. Antacids are documented not to significantly affect fluconazole absorption.

Mechanism of Action

The action of Флукорал (Fluconazole) is defined by a highly targeted biological process that compromises the structural integrity of the fungal cell membrane. The mechanism operates entirely within the pathogen, focusing on a critical enzymatic bottleneck unique to the fungal organism.

Targeted Inhibition of Fungal Enzyme Activity

Флукорал exerts its primary effect by acting as a highly selective inhibitor of the fungal enzyme Lanosterol 14-alpha-demethylase ( CYP51). The drug's molecular structure forms a stable bond with the enzyme's heme iron, effectively blocking the CYP51 from carrying out its function of converting lanosterol.

Disruption of the Cell Membrane Biosynthesis Pathway

The enzymatic block immediately interrupts the pathogen's ergosterol biosynthesis pathway. This prevents the necessary synthesis of the ergosterol structural component, while simultaneously causing an accumulation of toxic, metabolically irrelevant molecules, the 14alpha-methylated sterols. This physiological consequence leads to a severe compromise in the fungal cell membrane's fluidity and structural stability, ultimately resulting in cellular leakage and inhibition of fungal proliferation.

Limitations and Constraints on the Mechanism

The drug's mechanism can be challenged by certain biological changes within the fungus. These constraints include the upregulation of membrane efflux pumps ( CDR1, MDR1), which actively remove the drug from the cell, or point mutations in the target CYP51 enzyme that reduce the drug's binding affinity, both leading to a failure to achieve the required level of enzymatic inhibition.

Dosage and Administration Information

How to Use Флукорал (Fluconazole)

Флукорал is administered through two official routes: Oral (via capsules, tablets, or liquid suspension) and Intravenous (IV) infusion, with the IV route typically reserved for patients who cannot tolerate oral administration. Its use is highly dependent on a structured regimen that dictates the route, frequency, and duration of therapy, but not its clinical effectiveness or safety.

Official Dosing and Administration Principles

Most regimens begin with an initial Loading Dose on Day 1, which is often double the subsequent daily dose, followed by a consistent Maintenance Dose. For instance, uncomplicated vaginal candidiasis is commonly managed with a 150 mg single oral dose. In contrast, severe systemic infections may necessitate doses up to 800 mg per day. Due to the drug's half-life, the maintenance dose is typically administered once daily.

Administration Constraint	Official Requirement
Timing with Food	May be taken with or without food.
IV Infusion Rate	Must be infused slowly, generally at a rate not exceeding 200 mg/hour.
Oral Suspension	Must be shaken well and measured with a calibrated dosing device to ensure accurate intake.

Population-Specific Use

Dosing must be adjusted for patients with impaired kidney function, as the drug is primarily cleared by the kidneys. For adults on multiple-dose therapy with creatinine clearance of 50 mL/min or less, the subsequent daily dose is typically reduced by 50%. Pediatric dosing follows specific weight-based (mg/kg) schedules. If a dose is missed, it should be taken when remembered, but must be skipped if it is almost time for the next scheduled dose to avoid taking a double dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Флукорал

Evidence for Systemic Fungal Infections

This section summarizes the evidence base for the use of Флукорал in systemic fungal conditions that affect internal organs, such as Candidemia and disseminated infections. The content outlines the types of Randomized Controlled Trials (RCTs) and observational studies that have examined endpoints like outcomes related to fungal-free survival and microbiological clearance.

Флукорал (Fluconazole) was studied for use in adults with Systemic Candida Infections. Research describes patterns in fungal clearance rates observed in certain study populations, particularly non-neutropenic adults. Studies monitored the overall mortality rates, which served as a primary endpoint in many trials. Long-term effects are not fully established for all patients recovering from these infections; follow-up durations were often limited.

Evidence for Prevention of Infection (Prophylaxis)

This section outlines the research available on using Флукорал to prevent fungal infections in high-risk patients. It describes the placebo-controlled RCTs that studied the incidence of invasive fungal infection (IFI) in specific, vulnerable groups like very low birth weight neonates and transplant recipients.

Research explored the observed incidence of IFI in high-risk patients who received the treatment versus controls. For these specific, well-defined groups, findings describe patterns observed in the rate of systemic fungal infection. Data are still emerging regarding the long-term impact of this type of preventive treatment on the overall spectrum of fungi that may colonize a patient.

Evidence for Cryptococcal Disease and Mucosal Infections

This area summarizes the research supporting the use of the drug for both acute and long-term management of Cryptococcal Meningitis and common conditions like Oropharyngeal and Vaginal Candidiasis. The summary details the outcomes tracked in clinical trials, such as recurrence rates and symptomatic resolution.

For Cryptococcal Meningitis, trials compared the frequency of disease recurrence in patients who continued long-term maintenance treatment versus control groups, such as those who received placebo. For mucosal infections, studies examined the clinical response rate (tracking changes in patient-reported discomfort) and mycological cure rate (tracking the absence of the organism). Research describes the proportions of patients who reported symptomatic resolution by the end of the treatment period.

Uncertainty and Research Gaps in the Evidence

The evidence landscape is not complete, and research is ongoing. Subgroup findings are uncertain when trying to apply trial results to patients with unusual or rare combinations of health issues, as the sample sizes were modest for these highly specific cohorts. For certain less common indications, the evidence quality varies across studies, often relying on retrospective data. This means certainty remains low for long-term outcomes in these specific contexts.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Флукорал (FAQ)

Q: Why do doctors often prescribe a loading dose of Флукорал?

Official regulatory documents explain that starting treatment with a loading dose is common. This initial dose is typically higher than the subsequent daily maintenance dose. The purpose is to help the medication quickly reach effective levels in the bloodstream, known as steady-state plasma concentrations, which is necessary because of the drug's long elimination time from the body.

Q: Is it normal for my stomach to feel a little upset when I first start taking Флукорал?

According to official product information, gastrointestinal side effects are classified as Common adverse reactions, meaning they occur in one out of every 100 patients or more. These symptoms can include nausea, stomach pain, diarrhea, or vomiting. This indicates that mild stomach upset is a known and relatively frequent effect.

Q: Can Флукорал affect the results of blood tests?

Official safety information documents several changes that have been measured in clinical studies. Specifically, the regulatory profile notes the potential for increases in liver enzymes and the possibility of anemia (a reduction in red blood cells) as documented adverse reactions that may be detected through standard blood testing.

Q: What are the most commonly reported side effects people mention in forums?

Official regulatory data classifies adverse reactions based on how often they occur in clinical studies. The most Common side effects, reported in 1 in 100 patients, are generally headache and issues related to the gastrointestinal tract, such as nausea, abdominal pain, and diarrhea.

Q: Does Флукорал interact with common pain relievers like ibuprofen?

The official product information does not explicitly name ibuprofen, a common pain reliever. However, Флукорал is known to inhibit certain Cytochrome P450 enzymes in the liver, such as CYP2C9, which metabolize various other medicines. This mechanism suggests a potential for interaction with other drugs, and patients should review all co-administered medications with a healthcare provider.

Q: How quickly does Флукорал leave the body after I stop taking it?

The time it takes for a drug to be cleared is related to its half-life. Official pharmacological data indicates that Флукорал has a relatively long half-life, approximately 20 to 30 hours in adults with normal kidney function. The medicine is primarily processed and eliminated from the body by the kidneys.

Q: Is Флукорал safe to take if I have liver concerns, even if minor?

Regulatory documents advise that caution is required for any patient with pre-existing liver dysfunction. Serious hepatic toxicity, including rare cases of liver failure, is a documented risk. Official documentation indicates that patients with existing liver conditions may require close clinical monitoring during use.

Q: What are the most serious, but rare, side effects people search for online?

Official safety profiles highlight several serious adverse reactions, although they are rare. These can include effects on heart rhythm, such as QT prolongation, which may lead to Torsade de pointes, severe skin reactions like Stevens-Johnson syndrome, and serious hepatic failure.

Q: Can I use Флукорал if I have an existing kidney condition?

Because Флукорал is mainly cleared by the kidneys, official guidelines indicate that its use and dosage may need to be adjusted for patients with impaired kidney function. This is often necessary to prevent the medicine from accumulating in the body and is a factor in determining suitability for use.

Q: Are there any long-term health effects associated with multiple courses of Флукорал?

Regulatory safety reviews have specifically noted that the use of chronic, high doses (between 400 and 800 mg per day) during the first trimester of pregnancy has been associated with a risk of distinct congenital anomalies. This risk is primarily associated with sustained high-dose use during this specific period.

Q: Is a metallic taste in the mouth a known side effect of Флукорал?

Official safety data lists 'taste perversion' as an uncommon adverse effect. While the specific description of a 'metallic taste' is not detailed in the regulatory label, a change or disturbance in taste is a documented side effect.

Q: Can Флукорал be taken while on allergy medication?

This medicine is contraindicated (absolutely prohibited) for use with other medications that both prolong the QT interval and are metabolized by the CYP3A4 enzyme. Because some allergy medications fall into this category, it is important to review potential interactions with a healthcare professional.

Q: What are people asking about Флукорал and hair loss online?

Official regulatory product information documents alopecia (hair loss) as a rare adverse reaction associated with Флукорал treatment. This means that while it is an officially recognized side effect, it does not occur frequently in patients.

Q: Why does the packaging for Флукорал emphasize liver monitoring?

The emphasis on monitoring is due to the potential for serious hepatic toxicity, which is documented in the official safety profile. Although rare, cases of liver failure have been reported, which is why the official documentation requires caution and may recommend clinical monitoring.

Q: Are there any known interactions with herbal supplements like St. John's wort?

Official interaction guidelines caution against taking Флукорал with substances that affect the Cytochrome P450 enzyme system, particularly CYP3A4 and CYP2C9. Herbal supplements like St. John's wort can affect these enzymes, creating a potential for interaction that requires review.

Q: Why is Флукорал often a first-line treatment option?

Regulatory documents classify Флукорал as a triazole antifungal known for its broad effectiveness against various fungi. Its high oral bioavailability—meaning the body absorbs more than 90% of the oral dose—is a key pharmacological property that supports its profile as a common therapeutic option.

Q: What conditions make someone unsuitable for taking Флукорал?

Use is prohibited for anyone with a documented allergy or hypersensitivity to fluconazole or similar azole antifungals. Use is conditional and requires caution for patients with existing liver dysfunction, renal impairment, or certain proarrhythmic cardiac conditions that increase the risk of heart rhythm problems.

Q: Do children take the same kind of Флукорал as adults?

While Флукорал is approved for use across a wide age range, including term newborns, the format and dose differ. Children often receive the liquid oral suspension formulation, and their dosage is calculated based on their weight in milligrams per kilogram, rather than a fixed adult dose.

Q: What are the non-drug interactions to be aware of while on Флукорал?

Official regulatory documents specifically address non-drug factors such as food and alcohol. The medication may be taken with or without food, as absorption is not significantly affected. Furthermore, alcohol is not explicitly listed as a drug interaction in the official product information.

How should Флукорал be stored and disposed of?

How to Store and Dispose of Fluconazole (Флукорал)

Storage and disposal must strictly follow official regulatory requirements to maintain product integrity and safety.

️ Storage Requirements

Formulation	Required Temperature	Stability/Handling Rule
Tablets/Dry Powder	Store below 30 C (86 F)	Protect from moisture.
Reconstituted Suspension	Store between 5 C and 30 C	Do not freeze. Discard after 14 days.

All forms must be stored out of the sight and reach of children.

️ Disposal Instructions

Unused or expired medicine must be disposed of according to local regulations and pharmaceutical waste procedures. It is specified that the medicine should not be disposed of via household waste or flushed into wastewater systems.

Флукорал